Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Birrer

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Princess Takamatsu Symposia|January 1, 1986
Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancerJ D Minna, J F Battey, M Birrer, et al.
The Journal of Biological Chemistry|January 5, 2000
Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6)J S Park, S Boyer, K Mitchell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Princess Takamatsu Symposia|January 1, 1986
Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancerJ D Minna, J F Battey, M Birrer, et al.
The Journal of Biological Chemistry|January 5, 2000
Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6)J S Park, S Boyer, K Mitchell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Pageof 4